Bp Plc held its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the second quarter, Holdings Channel reports. The fund owned 24,000 shares of the medical equipment provider’s stock at the end of the second quarter. Bp Plc’s holdings in Zimmer Biomet Holdings were worth $3,081,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of ZBH. Ledyard National Bank boosted its position in Zimmer Biomet Holdings by 9.3% in the first quarter. Ledyard National Bank now owns 1,293 shares of the medical equipment provider’s stock valued at $157,000 after buying an additional 110 shares in the last quarter. DnB Asset Management AS boosted its position in Zimmer Biomet Holdings by 16.2% in the first quarter. DnB Asset Management AS now owns 22,208 shares of the medical equipment provider’s stock valued at $2,712,000 after buying an additional 3,100 shares in the last quarter. Farmers & Merchants Investments Inc. boosted its position in Zimmer Biomet Holdings by 3.2% in the first quarter. Farmers & Merchants Investments Inc. now owns 2,555 shares of the medical equipment provider’s stock valued at $312,000 after buying an additional 80 shares in the last quarter. Heritage Investors Management Corp boosted its position in Zimmer Biomet Holdings by 3.6% in the first quarter. Heritage Investors Management Corp now owns 110,855 shares of the medical equipment provider’s stock valued at $13,537,000 after buying an additional 3,837 shares in the last quarter. Finally, Fox Run Management L.L.C. acquired a new position in Zimmer Biomet Holdings during the first quarter valued at $232,000. Hedge funds and other institutional investors own 83.62% of the company’s stock.

Shares of Zimmer Biomet Holdings, Inc. (NYSE ZBH) opened at 112.86 on Thursday. The firm’s 50-day moving average price is $125.96 and its 200 day moving average price is $121.36. Zimmer Biomet Holdings, Inc. has a 12-month low of $95.63 and a 12-month high of $133.49. The company has a market cap of $22.78 billion, a price-to-earnings ratio of 32.14 and a beta of 1.20.

Zimmer Biomet Holdings (NYSE:ZBH) last posted its earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 EPS for the quarter, missing the Zacks’ consensus estimate of $2.10 by $0.02. Zimmer Biomet Holdings had a net margin of 9.12% and a return on equity of 16.70%. The business had revenue of $1.95 billion for the quarter, compared to analyst estimates of $1.95 billion. During the same quarter last year, the business earned $2.02 earnings per share. Zimmer Biomet Holdings’s revenue was up 1.1% on a year-over-year basis. On average, analysts predict that Zimmer Biomet Holdings, Inc. will post $8.24 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Friday, September 22nd will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.85%. The ex-dividend date is Thursday, September 21st. Zimmer Biomet Holdings’s dividend payout ratio (DPR) is presently 27.59%.

ILLEGAL ACTIVITY NOTICE: “Bp Plc Has $3,081,000 Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)” was first posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/08/10/bp-plc-has-3081000-stake-in-zimmer-biomet-holdings-inc-nysezbh.html.

Several research firms have recently weighed in on ZBH. Morgan Stanley boosted their price target on Zimmer Biomet Holdings from $137.00 to $150.00 and gave the stock an “overweight” rating in a research note on Monday, July 17th. Stifel Nicolaus restated a “hold” rating and issued a $125.00 price target on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Piper Jaffray Companies restated a “buy” rating and issued a $141.00 price target on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Canaccord Genuity restated a “buy” rating and issued a $141.00 price target on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Finally, Wells Fargo & Company restated a “market weight” rating on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Four research analysts have rated the stock with a sell rating, seven have given a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $137.76.

In related news, VP Tony W. Collins sold 16,986 shares of Zimmer Biomet Holdings stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $121.74, for a total value of $2,067,875.64. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Sang Yi sold 17,731 shares of Zimmer Biomet Holdings stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $124.56, for a total value of $2,208,573.36. The disclosure for this sale can be found here. 1.07% of the stock is owned by company insiders.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.